Myriad Genetics (NASDAQ:MYGN) traded higher on Wednesday after Piper Sandler upgraded the cancer test developer to Overweight ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...

Myriad Genetics earned $4 million from GeneSight testing via UnitedHealthcare in 2024. Myriad reaffirms 2025 EPS guidance of $0.07-$0.11 vs. consensus of $0.06. Every week, our Whisper Index ...

Myriad Genetics Chief Executive Paul J. Diaz will leave the company April 30 to return to private equity firm Cressey & Co., where he will be a managing partner. The former Kindred Healthcare CEO was ...

Gabbi’s telehealth solution provides logistics and educational support to assess breast cancer risk. Patients identified as potentially high risk are connected with a Gabbi clinician to be evaluated ...

StockNews.com lowered shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a buy rating to a hold rating in a research report sent to investors on Thursday morning. Other equities analysts have ...

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025 ...